Midtown Biotech Dianthus Therapeutics Launches $625M Stock Offering to Advance Autoimmune Drug Pipeline
Midtown biotech Dianthus Therapeutics is raising $625 million through a stock offering to fund clinical development of autoimmune disorder treatments.



